islatravir
FDA Accepts NDA for Merck’s Once-Daily, Oral, 2-Drug Regimen for HIV-1 Treatment
The FDA accepted for review the New Drug Application for doravirine-islatravir, an investigational, once-daily, ...
JULY 10, 2025
Key Takeaways for PrEP, HIV Treatment and Other Infectious Diseases
CROI 2025 highlighted promising therapeutic modalities for HIV treatment and prevention.
JULY 3, 2025
Long-Acting Oral Combo for HIV Maintains Viral Suppression at Week 24
Most patients with HIV taking the investigational combination of islatravir (ISL; Merck) plus lenacapavir ...
JUNE 17, 2024
Uncertain Future for 2 Long-Acting HIV Therapies
The approvals have been put on hold for two major new long-acting HIV therapies, lenacapavir (LEN, Gilead) and ...
MARCH 30, 2022
Load more